Angelo Vanzulli

Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial

Andrea Sartore‐Bianchi, Livio Trusolino, Cosimo Martino et al. · The Lancet Oncology · 2016 · 984 citations · Full text

Oncology, Medicine, Pathology +5

Intramyocellular triglyceride content is a determinant of in vivo insulin resistance in humans: a 1H-13C nuclear magnetic resonance spectroscopy assessment in offspring of type 2 diabetic parents.

Gianluca Perseghin, Paola Scifo, Francesco De Cobelli et al. · Diabetes · 1999 · 876 citations

Insulin Resistance, Metabolic Syndrome, Nutrition +13

Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)

Alexander Drilon, Salvatore Siena, Sai‐Hong Ignatius Ou et al. · Cancer Discovery · 2017 · 795 citations · Full text

Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer

Andrea Sartore‐Bianchi, Elena Ardini, Roberta Bosotti et al. · JNCI Journal of the National Cancer Institute · 2015 · 245 citations · Full text

Radiation Oncology, Systems Biology, Oncology +15

Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial

Andrea Sartore‐Bianchi, Filippo Pietrantonio, Sara Lonardi et al. · Nature Medicine · 2022 · 237 citations · Full text